This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone quarter ended Sep 2026: revenue Rs 7,291m, up 30.4%; profit after tax Rs 623m, up 14.9%
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue from operations for the quarter ended September 30, 2026 was Rs 7,291 million, up 30.4% from Rs 5,591 million in the Sep 2025 quarter. Profit after tax was Rs 623.3 million versus Rs 542.2 million, up 14.9%. Exceptional items were a Rs 149.6 million charge, and operating profit margin fell to 11.1% from 12.5%. NPPA's Rs 1,486.6 million overcharging demand was disclosed; no provision was made as the court paused collection.
Revenue growth supports sentiment, but weaker operating margins, exceptional costs and the unresolved NPPA demand raise profit and price risk.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹729.1 Cr | ₹559.1 Cr | +30.4% |
| Operating profit | ₹88.33 Cr | ₹71.94 Cr | +22.8% |
| Profit after tax | ₹62.33 Cr | ₹54.22 Cr | +15.0% |
| EBITDA margin | 11.1% | 12.5% | −1.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.